Comparison of Different Muscle-Relaxant Anesthetics On

Total Page:16

File Type:pdf, Size:1020Kb

Comparison of Different Muscle-Relaxant Anesthetics On ANTICANCER RESEARCH 37 : 4371-4378 (2017) doi:10.21873/anticanres.11831 Comparison of Different Muscle-Relaxant Anesthetics on Growth, Migration and Invasion of Gastric Cancer Cells AIHUA JIANG 1* , HUISHAN ZHAO 1* , XIAOFEI LIU 1, MINGWEI YU 1, JIAN CHEN 1 and WEN G. JIANG 2 1Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China; 2Cardiff-China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, U.K. Abstract. Background/Aim: Muscle relaxants, also known treatment for GC includes radiotherapy, routine surgery, as neuromuscular blocking agents, can block nerve hormone therapy and biotherapy. However, when tumors impulses to the muscles and are always used in surgery for progress there is a risk that not all of the tumor tissue is general anesthesia. However, the effect of muscle-relaxant surgically removed (3, 4). Anesthetics are administered to anesthetics on cell activity in gastric cancer is currently facilitate surgery. Some factors including anesthetic unknown. The present study aimed to examine and techniques and anesthetic drugs may affect the activity of compare the role of three different muscle-relaxant residual tumor cells after surgery and facilitate cancer anesthetics in gastric cancer cells. Materials and Methods: recurrence and/or metastasis (5). Gastric cancer cells (SGC7901 and BGC 823) were Tumor metastasis is the spread of cells from the primary treated with a different dose of muscle-relaxant tumor to new locations in the body, through the circulatory anesthetics, Rocuronium bromide (Rb), Vecuronium and lymphatic system, and is considered the main cause of bromide (Vb) and Cisatracurium Besilate (CB). Using in cancer-related death. Metastatic tumor cells show different vitro models, the effects on gastric cancer cell invasion, genomic and epigenetic profiles generally associated with growth and migration of various anesthetics were aggressive traits. The analgesia technique and the anesthetic subsequently investigated. Results: We found that Rb agents used during surgical tumor resection have been increased the growth, invasion and migration of gastric determined as pathogenic factors for cancer recurrence/ cancer cells SGC7901 and BGC823. However, Vb and CB, metastasis. Thus, anesthesiologists take enormous as relatively mitigative anesthetics, did not significantly responsibility in decreasing metastasis/recurrence rate of affect gastric cancer cell malignant phenotype at their cancer, both during the perioperative period and postoperative regular blood concentration. Conclusion: Our results are analgesia period. There is evidence to suggest that anesthetics important in selecting the type and dose of anesthetic used may potentially have a role in tumor metastasis (6-8). A better for surgery of gastric cancer patients. An understanding of understanding of the mechanisms of metastatic disease and the effect of muscle-relaxant anesthetics and their impact identification of regulators of metastasis, including how on tumor metastasis is critical, since it provides insight metastatic tumor cells invade and grow in the local into the appropriate anesthetic strategy that could improve microenvironment, would enable the treatment and long-term survival in some patients with gastric cancer. development of metastatic prevention strategies. Gastric cancer (GC) is a highly lethal malignancy The effect of anesthetics on cancer metastasis has been worldwide, particular in developing countries, which makes unveiled gradually. Some anesthetics were considered an it a key public health problem (1, 2). The conventional important factor in cancer metastasis. Recently, a review summarized the effect of anesthesia on tumor metastasis, including anesthetic and analgesic techniques (5), suggesting that anesthetics are a non-negligible issue in *These Authors contributed equally to this study. clinical practice. Propofol was investigated in several kinds of cancers and in gastric cancer has been shown to have an Correspondence to: Prof. Wen G. Jiang, Cardiff-China Medical inhibitory role in the growth and survival of gastric cancer Research Collaborative, Cardiff University School of Medicine, cells through up-regulating ING3 (9). In another study Heath Park, Cardiff CF14 4XN, U.K. Tel: +44 2920687065, e-mail: [email protected] propofol inhibited proliferation and apoptosis by regulating microRNA-451 and MMP-2 expression (10). Propofol has Key Words: Anesthetics, migration, breast cancer, invasion, Rb, Vb, also been shown to have an effect on the metastasis of CB. other cancer cells such as ovarian (11), lung (12) and 4371 ANTICANCER RESEARCH 37 : 4371-4378 (2017) Figure 1 . Chemical structures of Rb (A), Vb (B) and CB (C). prostate cancer (13). Increasing numbers of reports on clinical dosages used by the anesthesiologist for which Rb, Vb and procaine have suggested that low dosage of procaine CB were 0.6 mg/kg, 0.1 mg/kg and 0.2 mg/kg respectively. Dilution suppressed the proliferation of lung cancer cells, however ranges were as follows: Rb - 8/80 μg/ml, Vb - .5/15 μg/ml and CB - 2.5/25 μg/ml. this did not appear with higher doses (14). Procaine has also been seen to affect osteosarcoma cells, by inhibiting In vitro cell growth assays. For each cell line 3,000 cells/200 μl/well their migration and growth possibly through inducing cell were added to a 96-well plate (BEAVER, Suzhou, China) and apoptosis (15). Muscle relaxants, including Rocuronium incubated for 1 to 5 days (1, 3, 4 and 5 days respectively). After bromide (Rb), Vecuronium bromide (Vb) and Cisatracurium incubation, culture medium was removed and replaced with 100 μl Besilate (CB), act as effective anesthetics by blocking the of 10% CCK-8 (Cell Counting Kit-8, Dojindo, Japan). Absorbance nerve impulses to the muscles, and thus are generally used of the solution was determined using a spectrophotometer (Thermo in surgery for general anesthesia. Currently there is little Fisher Scientific) at a wavelength of 450 nm. research on the effect of muscle relaxants on tumor In vitro cell scratch assay. Cells were seeded into 12-well plates and metastasis. Last year, our team concentrated on muscle cultured overnight to allow the formation of a confluent monolayer. relaxants’ impact on breast cancer metastasis. Interestingly, Subsequently an artificial wound in the monolayer was created by we found that Rb promoted breast cancer cell growth, using a 200- μl pipette tip to scratch a wound. The cell monolayer migration and invasion, but Vb did not (16). In this study, was washed twice with PBS to remove floating cells. Migration of we investigated how muscle relaxants affect the activity of cells, monitored by the closing of the artificial wound space was gastric cancer cells. recorded every 6 h using an inverted microscope over a period up to 24 h. The sizes of the wounds were subsequently analyzed using Image J software. Materials and Methods In vitro cell adhesion assay. Six-well plates were pre-coated with 5 Cell culture. Gastric cancer cells SGC7901 and BGC 823 were μg/100 μl/well Matrigel (BD Matrigel™ Basement Membrane obtained from China Centre for Type Culture Collection (Shanghai, Matrix, Corning, Tewksbury MA, USA) diluted in serum free media China). These two wild-type cancer cells were routinely cultured in and dried to form an artificial basement membrane. Following RPMI-1640 (Life Technologies Corporation, USA) supplemented rehydration with serum-free media for 40 min, 20,000 cells/200 μl with 10% foetal calf serum (FCS; PAA Laboratories, Somerset, were added into each well. After 4 min incubation culture medium UK), penicillin and streptomycin (Sigma-Aldrich Inc, Poole, Dorset, was removed and the wells were washed with PBS to remove any UK)), in an incubator at 37.0˚C, 5% CO 2 and 95% humidity. non-adherent cells. Adherent cells were fixed with 4% formalin for Muscle relaxants for anesthesia. Three kinds of muscle relaxant 30 min. After washing each well twice with PBS, adherent cells were anesthetics, Rb, Vb and CB, were purchased from Sigma (Sigma- stained with 0.5% crystal violet. Crystal violet staining was dissolved Aldrich, Dorset, UK). They were all dissolved in PBS and stored at with 10% acetic acid and measured using a spectrophotometer 4˚C until use. The doses used during experiments were based on the (Thermo Fisher Scientific) at a wavelength of 540 nm. 4372 Jiang et al : Muscle-relaxant Anesthetics and Gastric Cancer Figure 2. Effects of Rb, Vb and CB on growth of gastric cancer cells in vitro. Rb increased the proliferation of SGC7901 (A) and BGC823(B) in vitro. Vb had no significant effect on the growth of SGC7901 (C) and BGC823 (D) cells. CB hardly stimulated the growth of SGC7901 (E) and BGC823(F) in vitro, but overdose could result in partial cell death (*p<0.05, **p<0.01 vs. control with no treatment). 4373 ANTICANCER RESEARCH 37 : 4371-4378 (2017) Figure 3. The effect of Rb, Vb and CB on migration of gastric cancer cells in vitro. A: Rb promoted the migration of SGC7901 (A) and BGC823 (B). Vb had no effect on the migration of SGC7901(C) and BGC823 (D) at the regular blood concentration in vitro, but facilitated the migration at tenfold blood concentration. CB hardly affected SGC7901 (E) and BGC823 (F) migration in vitro. 4374 Jiang et al : Muscle-relaxant Anesthetics and Gastric Cancer Figure 4. The effect of Rb, Vb and CB on adhesion of gastric cancer cells. Rb increased the adhesion of SGC7901 (A) at tenfold blood concentration in vitro. Rb and Vb affected the adhesion of BGC823 (B) and reached statistical significance. Representative data of adhesion assay for SGC7901 and BGC823 cells treated with different concentration of muscle-relaxant anesthetics for 40 min (C). In vitro cell invasion assay. Transwell chambers (8- μm pore size) Rb promoted gastric cancer cell growth. When compared to polycarbonate filter inserts (6.5 mm diameter) (Becton Dickinson and the untreated control group Rb resulted in a significant increase Company, Oxford, UK), were coated with 50 μg Matrigel/100 μl/insert in gastric cancer cell growth, in SGC7901 ( p< 0.05) (Figure (BD Matrigel™ Basement Membrane Matrix) and air-dried.
Recommended publications
  • A Comparative Study of Neuromuscular Blocking Effects
    IndianJournalofAnesthesiaandAnalgesia OriginalResearchArticle January–February2020;7(1)(Part-I):58-63 DOI:http://dx.doi.org/10.21088/ijaa.2349.8471.7120.9 AComparativeStudyofNeuromuscularBlockingEffectsandReversibility ofCisatracuriumandVecuronium DivyaNKheskani1,HeenaSChhanwal2,BhaktiSJain3 1AssistantProfessor,2ProfessorandHead,3rdYearResident,DepartmentofAnaesthesia,GCSMedicalCollege,Hospital&Research Centre,NearChamundaBridge,Ahmedabad,Gujarat380025,India. Abstract Context: Cisatracurium is a cis isomer of parent compound atracurium, devoid of histamine release, thus possessing hemodynamic & cardiovascular stability. Aims: We compared the intubating conditions, hemodynamic stability & recovery of atracurium & vecuronium. Settings and Design: We carried out prospective, double blind randomized study after approval of ethical committee. 100 adult patients of ASA 1 &2with comparable demographicdatawereselected. Dividedin TwoGroupsC(Cisatracurium) &V(Vecuronium).Standardmonitoringwasdone&followingroutinepremedication&inductionagents, patientswereintubatedat2minsafteradministrationofcisatracurium0.15mg/kg&vecuronium0.1mg/ kgrespectively,maintainedonintermittentdoseofcisatracurium:0.03mg/kg&vecuronium:0.02mg/kg. IntubationconditionswereassessedaccordingtoTimeto25%recoveryoft1/tcfollowinginitialdoses,Time to25%recoveryoft1/tcfollowingrepeatedboluses,Timeto25%recoveryoft1/tcfollowinglastdose,Return oft4/t1ratio0.8spontaneousrecoveryatendofoperation.Statisticalanalysisused:Theresultswereevaluated byapplyingpairedt-testandp-valueusingSPSSStatisticalSoftware.Results:Intubatingconditionsat2mins
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Cost Analysis and Safety Comparison of Cisatracurium and Atracurium in Patients Undergoing General Anesthesia
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2013; 17: 447-450 Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia A. MOVAFEGH, S. AMINI*, H. SHARIFNIA, H. TORKAMANDI*, A. HAYATSHAHI*, M. JAVADI* Intensive Care Unit, and *Pharmaceutical Care Department; Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Abstract. – BACKGROUND : Non-depolarizing Introduction neuromuscular blocking agents (NMB) differ in pharmacokinetic and pharmacodynamic parame - The introduction of neuromuscular blocking ters. An anesthesiologist according to these simi - larities and differences is able to choose the least agents in 1942 into anesthetic practice was an im - costly one if the same safety profile and same clin - portant development. Non-depolarizing NMB ical benefit achieved with the different alternatives. agents differ in the onset of action, duration of ac - AIM: The main objective of this study is to eval - tion, metabolic route, potency, adverse effects and uate the economic and adverse drug reactions cost. An anesthesiologist is able to choose NMB prevalence and differences between cisatracurium drugs according to these similarities and differ - and atracurium the two non-depolarizing NMB 1,2 drugs, which are widely used in adult patients un - ences . Atracurium and Cisatracurium are two dergoing surgery with general anesthesia in a non-depolarizing NMB agents with intermediate teaching Hospital in Iran. duration of action 1. Cisatracurium besilate is the MATERIALS AND METHODS : A cost analysis R-cis isomer of atracurium besilate and is 3-4 fold and adverse drug reactions (ADR) monitoring more potent than atracurium 3. Compared with were performed.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Observations on the Use of Different Modes of Cisatracurium Administration in Hyperthermic Intraperitoneal Chemotherapy
    Observations on the Use of Different Modes of Cisatracurium Administration in Hyperthermic Intraperitoneal Chemotherapy Jing Zhang Capital Medical University Aliated Beijing Shijitan Hospital Danyang Gao Capital Medical University Aliated Beijing Shijitan Hospital https://orcid.org/0000-0002-8491-5376 Pengfei Liu Capital Medical University Aliated Beijing Shijitan Hospital Tianzuo Li ( [email protected] ) Capital Medical University Aliated Beijing Shijitan Hospital Research Article Keywords: Cis-atracurium, Intraperitoneal hyperperfusion chemotherapy (HIPEC), Anesthesia, Residual muscle relaxation Posted Date: April 12th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-392323/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Objective: To investigate the residual effects of cis-atracurium with different administrations in patients with hyperthermic intraperitoneal chemotherapy. Methods: 60 patients undergoing hyperthermic intraperitoneal chemotherapy were randomly divided into two groups with 30 cases in each group. All patients were induced with sufentanil 0.4ug/kg, propofol 2.0mg/kg and cis atracurium 0.2mg/kg. During the operation, sevourane and remifentanil were used to maintain anesthesia. BIS value was 45-55. The control group intermittently received cis-atracurium injection with 0.1mg/kg/h. The experimental group received continuous injection of cis-atracurium at a rate of 1.5ug/kg/min. Cis-atracurium was discontinued 30min before the end of the operation, sevourane inhalation was stopped 20min before the end of the surgery and remifentanil was discontinued 10min before the end. At the end of the operation, no muscle relaxant antagonism were applied. General information of patients was recorded.
    [Show full text]
  • The New Neuromuscular Blocking Agents: Do They Offer Any Advantages?
    British Journal of Anaesthesia 87 (6): 912±25 (2001) REVIEW ARTICLE The new neuromuscular blocking agents: do they offer any advantages? E. W. Moore* and J. M. Hunter² University Department of Anaesthesia, University Clinical Department, The Duncan Building, Daulby Street, Liverpool L69 3GA, UK *Corresponding author Br J Anaesth 2001; 87: 912±25 Keywords: neuromuscular block, aminosteroids; neuromuscular block, benzylisoquinoliniums; neuromuscular block, tropinyl diesters; neuromuscular block, tetrahydroisoquinolinium chlorofumarates The introduction of neuromuscular blocking drugs in 1942 animal and human studies. The bis-quaternary ammonium marked a new era in anaesthetic and surgical practice. The salt of bistropinyl diester G-1-64 is the most studied of the anaesthetist was enabled to provide respiratory support tropinyl diester group51 although investigations in humans during long and complex surgery whilst the surgeon was have yet to be reported (Fig. 3). allowed access to body cavities without voluntary or re¯ex muscle movement. In recent years, a generation of anaesthetists trained since atracurium and vecuronium GW280430A became available in 1982, have taken for granted the The structure of this mixed-tetrahydroisoquinolinium speed of onset, shorter and more predictable duration of chlorofumarate is given in Figure 2. The similarity in action, and lack of cardiovascular side-effects that these structure to mivacurium is demonstrated. The presence of drugs have in comparison with their predecessors.56 58 59 three methyl groups between the quaternary nitrogen and The latest generation of neuromuscular blocking drugs aims oxygen atom at each end of the carbon chain suggests that, to provide even greater advantages: as rapid an onset and similar to mivacurium, this compound will not undergo offset as succinylcholine; disposition independent of organ Hofmann degradation.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Anticancer Effects of Vecuronium Bromide and Cisatracurium Besylate
    G Model BIOMAG-154; No. of Pages 5 ARTICLE IN PRESS Biomedicine & Aging Pathology xxx (2014) xxx–xxx Available online at ScienceDirect www.sciencedirect.com Original article Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro a b,e c Iddrisu Baba Yabasin , Mohammed Mohammed Ibrahim , Abass Adam , d e a Sam-Awortwi Wilfred , Juventus Benogle Ziem , Peng Gao , f a,∗ Silvanus Kampo , Wen Qingping a Department of Anesthesiology, Dalian Medical University, 9 Western Section, Lvshun South Road, 116044 Dalian Liaoning, PR China b Department of Pathology and Pathophysiology, Dalian Medical University, 9 Western Section, Lvshun South Road, 116044 Dalian Liaoning, PR China c Department of Surgical Sciences, School of Medicine & Health Sciences, University for Development Studies, Box 1350, Tamale, Ghana d Department of Anesthesia, Komfo Anokye Teaching Hospital, Box 1934, Kumasi, Ghana e Department of Laboratory Science, School of Medicine & Health Sciences, University for Development Studies, Box 1350, Tamale, Ghana f Department of Anesthesia, School of Medicine & Health Sciences, University for Development Studies, Box 1350, Tamale, Ghana a r t i c l e i n f o a b s t r a c t Article history: Neuromuscular blocking drugs are used in anesthesia and intensive care to provide skeletal muscle relax- Received 10 April 2014 ation. However, literature has revealed that the effects of these drugs on cancer have not been widely Accepted 10 July 2014 studied. We tested the effects of two non-depolarising neuromuscular blocking drugs, vecuronium bro- Available online xxx mide and cisatracurium besylate on lung cancer cells’ (A549) proliferation, migration and viability in the presence of a cytotoxic drug, cisplatin.
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cisatracurium Strides 2 mg/ml solution for injection/infusion Cisatracurium Strides 5 mg/ml solution for injection/infusion Cisatracurium Strides 10 mg/ml solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg/ml 1 ml solution for injection/infusion contains Cisatracurium 2 mg as Cisatracurium besilate 2.68 mg. One vial of 5 ml solution contains 10 mg of Cisatracurium as Cisatracurium besilate. 5 mg/ml 1 ml solution for injection/infusion contains Cisatracurium 5 mg as Cisatracurium besilate 6.70 mg. One vial of 30 ml solution contains 150 mg of Cisatracurium as Cisatracurium besilate. 10 mg/ml 1 ml solution for injection/infusion contains Cisatracurium 10 mg as Cisatracurium besilate13.40 mg. One vial of 20 ml solution contains 200 mg of Cisatracurium as Cisatracurium besilate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion Colourless to slightly yellow or greenish yellow solution. Practically free from visible particulate matter. pH: 3.0-3.8 4. CLINICAL PARTICULARS Cisatracurium Strides is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous administration 4.1 Therapeutic indications 1 AT/H/0432/001-003/DC, REVISED final SmPC Cisatracurium Strides is indicated for use during surgical and other procedures and in intensive care in adults and children aged 1 month and over. Cisatracurium Strides can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation.
    [Show full text]
  • Texts Adopted by the European Phamacopoeia Commission
    © Pharmeuropa | Useful information | June 2015 1 List of texts adopted at the March 2015 session of the European Pharmacopoeia Commission NEW TEXTS GENERAL CHAPTERS 2.5.41. Methyl, ethyl and isopropyl benzenesulfonate in active substances 2.7.34. Assay of human C1-esterase inhibitor 5.19. Extemporaneous preparation of radiopharmaceuticals 5.21. Chemometric methods applied to analytical data MONOGRAPHS Vaccines for human use Haemophilus type b and meningococcal group C conjugate vaccine (2622) Radiopharmaceutical preparations and starting materials for radiopharmaceutical preparations Technetium (99mTc) oxidronate injection (2376) Herbal drugs and herbal drug preparations Aucklandia root (1797) Homoeopathic preparations Acidum picrinicum for homoeopathic preparations (2695) Histaminum for homoeopathic preparations (2671) Monographs Cisatracurium besilate (2763) Dienogest (2732) Entecavir monohydrate (2815) Gadobutrol monohydrate (2735) Gefitinib (2866) Human C1-esterase inhibitor (2818) Hydroxypropylcellulose, low-substituted (2083) Pregabalin (2777) Rabeprazole sodium (2868) 2 © Pharmeuropa | Useful information | June 2015 Rabeprazole sodium hydrate (2331) Ropinirole hydrochloride (2604) Sitagliptin phosphate monohydrate (2778) Sitagliptin tablets (2927) Sodium lauroylsarcosinate for external use (2542) Thiocolchicoside crystallised from ethanol (2896) Thiocolchicoside hydrate (2814) REVISED TEXTS GENERAL CHAPTERS 2.2.31. Electrophoresis 2.2.48. Raman spectroscopy 2.5.38. Methyl, ethyl and isopropyl methanesulfonate in active substances
    [Show full text]